CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells
- PMID: 19448142
- DOI: 10.1124/jpet.109.152710
CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells
Abstract
The CB(1) cannabinoid receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride (SR141716) has been shown by many investigators to inhibit basal G-protein activity, i.e., to display inverse agonism at high concentrations. However, it is not clear whether this effect is cannabinoid CB(1) receptor-mediated. Using the ligand-stimulated [(35)S]guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) assay, we have found that 10 microM SR141716 slightly but significantly decreases the basal [(35)S]GTPgammaS binding in membranes of the wild-type and CB(1) receptor knockout mouse cortex, parental Chinese hamster ovary (CHO) cells, and CHO cells stably transfected with micro-opioid receptors, MOR-CHO. Accordingly, we conclude that the inverse agonism of SR141716 is CB(1) receptor-independent. Although the specific MOR agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol (DAMGO) saturably and concentration-dependently stimulated [(35)S]GTPgammaS binding, SR141716 (10 microM) inhibited the basal by 25% and competitively inhibited DAMGO stimulation in the mouse cortex. In MOR-CHO membranes, DAMGO caused a 501 +/- 29% stimulation of the basal activity, which was inhibited to 456 +/- 22% by 10 microM SR141716. The inverse agonism of SR141716 was abolished, and DAMGO alone displayed weak, naloxone-insensitive stimulation, whereas the combination of DAMGO and SR141716 (10 microM each) resulted in a 169 +/- 22% stimulation of the basal activity (that was completely inhibited by the prototypic opioid antagonist naloxone) because of pertussis toxin (PTX) treatment to uncouple MORs from G(i)/G(o) proteins. SR141716 proved to bind directly to MORs with low affinity (IC(50) = 5.7 microM). These results suggest the emergence of novel, PTX-insensitive G-protein signaling that is blocked by naloxone when MORs are activated by the combination of DAMGO and SR141716.
Similar articles
-
Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors.Neurochem Int. 2012 Aug;61(3):378-88. doi: 10.1016/j.neuint.2012.05.015. Epub 2012 May 18. Neurochem Int. 2012. PMID: 22613132
-
Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling.J Pharmacol Exp Ther. 2004 Jul;310(1):256-62. doi: 10.1124/jpet.104.066837. Epub 2004 Mar 2. J Pharmacol Exp Ther. 2004. PMID: 14996951
-
Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors.J Biol Chem. 2008 Apr 25;283(17):11424-34. doi: 10.1074/jbc.M710300200. Epub 2008 Mar 4. J Biol Chem. 2008. PMID: 18319252
-
CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).J Clin Pharm Ther. 2012 Jun;37(3):260-5. doi: 10.1111/j.1365-2710.2011.01284.x. Epub 2011 Jul 11. J Clin Pharm Ther. 2012. PMID: 21740450 Review.
-
Role of protein kinase C in functional selectivity for desensitization at the mu-opioid receptor: from pharmacological curiosity to therapeutic potential.Br J Pharmacol. 2009 Sep;158(1):154-6. doi: 10.1111/j.1476-5381.2009.00198.x. Br J Pharmacol. 2009. PMID: 19719778 Free PMC article. Review.
Cited by
-
Modulation of Morphine Analgesia, Antinociceptive Tolerance, and Mu-Opioid Receptor Binding by the Cannabinoid CB2 Receptor Agonist O-1966.Front Pharmacol. 2022 Apr 21;13:803331. doi: 10.3389/fphar.2022.803331. eCollection 2022. Front Pharmacol. 2022. PMID: 35529434 Free PMC article.
-
Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking.PLoS One. 2012;7(1):e29900. doi: 10.1371/journal.pone.0029900. Epub 2012 Jan 26. PLoS One. 2012. PMID: 22291896 Free PMC article.
-
Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms.Front Pharmacol. 2017 Oct 10;8:720. doi: 10.3389/fphar.2017.00720. eCollection 2017. Front Pharmacol. 2017. PMID: 29066974 Free PMC article. Review.
-
Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.Pharmacol Ther. 2011 Dec;132(3):215-41. doi: 10.1016/j.pharmthera.2011.06.005. Epub 2011 Jul 18. Pharmacol Ther. 2011. PMID: 21798285 Free PMC article. Review.
-
AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.Neuropharmacology. 2012 Oct;63(5):905-15. doi: 10.1016/j.neuropharm.2012.06.046. Epub 2012 Jul 4. Neuropharmacology. 2012. PMID: 22771770 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials